" 210.1 
status of current good manufacturing practice regulations. 
(a) the regulations set forth in this part and in parts 211, 225, and 226 of this chapter contain the minimum current good manufacturing practice for methods to be used in, and the facilities or controls to be used for, the manufacture, processing, packing, or holding of a drug to assure that such drug meets the requirements of the act as to safety, and has the identity and strength and meets the quality and purity characteristics that it purports or is represented to possess. 
(b) the failure to comply with any regulation set forth in this part and in parts 211, 225, and 226 of this chapter in the manufacture, processing, packing, or holding of a drug shall render such drug to be adulterated under section 501(a)(2)(b) of the act and such drug, as well as the person who is responsible for the failure to comply, shall be subject to regulatory action. 
(c) owners and operators of establishments engaged in the recovery, donor screening, testing (including donor testing), processing, storage, labeling, packaging, or distribution of human cells, tissues, and cellular and tissue-based products (hct/ps), as defined in  1271.3(d) of this chapter, that are drugs (subject to review under an application submitted under section 505 of the act or under a biological product license application under section 351 of the public health service act), are subject to the donor-eligibility and applicable current good tissue practice procedures set forth in part 1271 subparts c and d of this chapter, in addition to the regulations in this part and in parts 211, 225, and 226 of this chapter. failure to comply with any applicable regulation set forth in this part, in parts 211, 225, and 226 of this chapter, in part 1271 subpart c of this chapter, or in part 1271 subpart d of this chapter with respect to the manufacture, processing, packing or holding of a drug, renders an hct/p adulterated under section 501(a)(2)(b) of the act. such hct/p, as well as the person who is responsible for the failure to comply, is subject to regulatory action. 

